Key Highlights
- Annexon will present post hoc analyses from its Phase 2 ARCHER trial at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting.
- The presentation will highlight baseline characteristics correlated with a confirmed loss of 15 letters in Best Corrected Visual Acuity (BCVA) among geographic atrophy patients.
- These findings are intended to refine patient selection strategies for the ongoing Phase 3 ARCHER-II clinical trial.
- Annexon remains on track to report pivotal topline data for vonaprument in geographic atrophy during the fourth quarter of 2026.
Annexon, Inc. (NASDAQ: ANNX) announced it will present post hoc analyses from its Phase 2 ARCHER trial at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting, offering the retina specialist community new insight into patient-level factors associated with disease progression in geographic atrophy ahead of the company's pivotal Phase 3 data later this year.
The presentation will specifically highlight baseline characteristics correlated with a confirmed loss of 15 letters in Best Corrected Visual Acuity (BCVA) among patients with geographic atrophy. BCVA is a standard clinical measure of vision quality used extensively in ophthalmology trials, and a 15-letter loss represents a clinically meaningful decline in visual function, making this analysis directly relevant to understanding which patients are most likely to experience significant vision deterioration.
Post hoc analyses of this kind, examining data after a trial's primary endpoints have already been assessed, are commonly used to generate hypotheses about which patient subgroups may derive the greatest benefit from a given therapy, or in this case, which baseline characteristics are most predictive of disease progression risk. While such analyses are exploratory in nature and carry less statistical weight than pre-specified primary endpoints, they can provide valuable clinical and trial-design insight.
Annexon has stated that these findings are intended to refine patient selection strategies for the ongoing Phase 3 ARCHER-II clinical trial. By better understanding which baseline patient characteristics correlate with faster or more severe vision loss, the company and independent investigators may be able to more precisely identify and enroll patients most likely to benefit from ANX007 (vonaprument) in future clinical and, eventually, real-world treatment settings.
This ASRS presentation arrives as an interim scientific data point ahead of the more consequential catalyst for Annexon: the company remains on track to report pivotal topline data for vonaprument in geographic atrophy during the fourth quarter of 2026, following the completion of Phase 3 ARCHER-II enrollment.
For the broader geographic atrophy treatment landscape, refined patient selection criteria of this kind could ultimately prove valuable not just for Annexon's own trial design, but for the field's broader understanding of disease progression patterns, informing how clinicians and researchers approach patient stratification in future geographic atrophy studies regardless of the specific therapy under investigation.






Please wait processing your request...